Barclays raised the firm’s price target on Twist Bioscience (TWST) to $50 from $39 and keeps an Overweight rating on the shares. The company is capitalizing on the AI drug disco market demand, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience Earnings Call Highlights AI-Driven Growth
- Midday Fly By: Disney slips despite Q1 beat, Devon to combine with Coterra
- Twist Bioscience rises 12.5%
- Twist Bioscience: Solid Execution, Raised 2026 Outlook, and Discounted Valuation Support Buy Rating
- Morning Movers: Disney dips following fourth quarter earnings